We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rws Holdings Plc | LSE:RWS | London | Ordinary Share | GB00BVFCZV34 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.20 | -1.22% | 177.60 | 177.40 | 178.00 | 179.40 | 177.40 | 179.00 | 848,768 | 16:35:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 718.2M | 47.5M | 0.1288 | 13.77 | 662.95M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/8/2020 08:19 | Excellent news if it was Makes SDL cheaper | phillis | |
27/8/2020 08:12 | Rws down c4.5% Pumped for the deal? Hmmm.... | redartbmud | |
27/8/2020 07:16 | So what No cash involved, using v high premium equity | phillis | |
27/8/2020 07:12 | ?? I take it as a negative for Rws. Maybe it will be viewed in a different light going forward. No future acquisitions in the pipeline for a long time. | redartbmud | |
07/8/2020 10:55 | Some more top slicing I think | phillis | |
07/8/2020 10:47 | New all time high. A quality business. | robinnicolson | |
17/7/2020 11:56 | Divis today :-) | phillis | |
22/6/2020 19:51 | Mail on Sunday 'Midas' update: | robinnicolson | |
13/6/2020 11:20 | A good piece on RWS by Richard Beddard: | robinnicolson | |
11/6/2020 12:04 | Phillis That was a good move. I was going to do it, but procrastinated. Hey ho.... | redartbmud | |
11/6/2020 11:47 | Inverse H&S?? | toffeeman | |
11/6/2020 11:40 | Top sliced a few at 657p Time to buy back? | phillis | |
11/6/2020 06:02 | RWS tipped as a buy | shanklin | |
10/6/2020 15:04 | IC recommends buying summarising as follows: "RWS is offsetting some Covid-19 challenges with new opportunities. For example, while life sciences has seen postponed clinical trials and cancelled elective procedures, some pharmaceutical customers, including Gilead (US:GILD), are requiring greater assistance as they develop Covid-19 treatments. Meanwhile, the balance sheet looks able to weather this crisis, the dividend has been maintained and long-term demand drivers – chiefly globalisation of digital content – remain unchanged. Buy." | alter ego | |
10/6/2020 14:25 | A minimal backward step due to a global pandemic. share price fall seems bizarre to me | shanklin | |
09/6/2020 10:33 | think this is the first time results have gone backwards | phillis | |
09/6/2020 10:28 | Well the market doesn't see them as being significant! | toffeeman | |
09/6/2020 10:07 | Very much so. Iconic Initial consideration of US$10.0m with additional deferred consideration of up to US$10.0m in RWS shares, subject to future performance. Revenues of US$1.2m for the year ended 31 December 2019 and an adjusted EBITDA* of US$23k. Revenues were up 100% on the previous year. Webdunia.com Total cash consideration of US$21.0m. Revenues of US$13.8m for the year ended 31 March 2020 and an adjusted EBITDA* of US$3.1m. Revenues were up 12% on the previous year and adjusted EBITDA was up by 33%. * EBITDA - profit before tax adjusted for interest, depreciation, amortization and other non-recurring costs. | orange1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions